Literature DB >> 25550219

Smac mimetics as IAP antagonists.

Simone Fulda1.   

Abstract

As the Inhibitor of Apoptosis (IAP) proteins are expressed at high levels in human cancers, they represent promising targets for therapeutic intervention. Small-molecule inhibitors of IAP proteins mimicking the endogenous IAP antagonist Smac, called Smac mimetics, neutralize IAP proteins and thereby promote the induction of cell death. Smac mimetics have been shown in preclinical models of human cancer to directly trigger cancer cell death or to sensitize for cancer cell death induced by a variety of cytotoxic stimuli. Smac mimetics are currently undergoing clinical evaluation in phase I/II trials, demonstrating that therapeutic targeting of IAP proteins has reached the clinical stage.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; Cell death; IAP proteins; Smac mimetic

Mesh:

Substances:

Year:  2014        PMID: 25550219     DOI: 10.1016/j.semcdb.2014.12.005

Source DB:  PubMed          Journal:  Semin Cell Dev Biol        ISSN: 1084-9521            Impact factor:   7.727


  38 in total

1.  Survivin Inhibitors Mitigate Chemotherapeutic Resistance in Breast Cancer Cells by Suppressing Genotoxic Nuclear Factor-κB Activation.

Authors:  Wei Wang; Bo Zhang; Arul M Mani; Zhongzhi Wu; Yu Fan; Wei Li; Zhao-Hui Wu
Journal:  J Pharmacol Exp Ther       Date:  2018-05-07       Impact factor: 4.030

Review 2.  Getting the "Kill" into "Shock and Kill": Strategies to Eliminate Latent HIV.

Authors:  Youry Kim; Jenny L Anderson; Sharon R Lewin
Journal:  Cell Host Microbe       Date:  2018-01-10       Impact factor: 21.023

3.  Clinicopathological and functional implications of the inhibitor of apoptosis proteins survivin and XIAP in esophageal cancer.

Authors:  Levent Dizdar; Lisa M Jünemann; Thomas A Werner; Pablo E Verde; Stephan E Baldus; Nikolas H Stoecklein; Wolfram T Knoefel; Andreas Krieg
Journal:  Oncol Lett       Date:  2018-01-09       Impact factor: 2.967

Review 4.  The role of apoptosis in acetaminophen hepatotoxicity.

Authors:  Hartmut Jaeschke; Luqi Duan; Jephte Y Akakpo; Anwar Farhood; Anup Ramachandran
Journal:  Food Chem Toxicol       Date:  2018-06-18       Impact factor: 6.023

5.  Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant.

Authors:  Jennifer Richmond; Alissa Robbins; Kathryn Evans; Dominik Beck; Raushan T Kurmasheva; Catherine A Billups; Hernan Carol; Sue Heatley; Rosemary Sutton; Glenn M Marshall; Deborah White; John Pimanda; Peter J Houghton; Malcolm A Smith; Richard B Lock
Journal:  Cancer Res       Date:  2016-06-14       Impact factor: 12.701

Review 6.  Therapeutic Small Molecules Target Inhibitor of Apoptosis Proteins in Cancers with Deregulation of Extrinsic and Intrinsic Cell Death Pathways.

Authors:  Adeeb Derakhshan; Zhong Chen; Carter Van Waes
Journal:  Clin Cancer Res       Date:  2016-12-30       Impact factor: 12.531

Review 7.  Regulated necrosis: disease relevance and therapeutic opportunities.

Authors:  Marcus Conrad; José Pedro Friedmann Angeli; Peter Vandenabeele; Brent R Stockwell
Journal:  Nat Rev Drug Discov       Date:  2016-01-18       Impact factor: 84.694

8.  Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer.

Authors:  Anne M Noonan; Kristen P Bunch; Jin-Qiu Chen; Michelle A Herrmann; Jung-Min Lee; Elise C Kohn; Ciara C O'Sullivan; Elizabeth Jordan; Nicole Houston; Naoko Takebe; Robert J Kinders; Liang Cao; Cody J Peer; W Douglas Figg; Christina M Annunziata
Journal:  Cancer       Date:  2015-11-13       Impact factor: 6.860

Review 9.  Glioblastoma and acute myeloid leukemia: malignancies with striking similarities.

Authors:  Eric Goethe; Bing Z Carter; Ganesh Rao; Naveen Pemmaraju
Journal:  J Neurooncol       Date:  2017-12-01       Impact factor: 4.130

10.  A Novel Inhibitor of Topoisomerase I Is Selectively Toxic for a Subset of Non-Small Cell Lung Cancer Cell Lines.

Authors:  Iryna O Zubovych; Anirudh Sethi; Aditya Kulkarni; Vural Tagal; Michael G Roth
Journal:  Mol Cancer Ther       Date:  2015-12-14       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.